Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
- Conditions
- Pulmonary EmbolismDeep Vein Thrombosis
- First Posted Date
- 2003-10-20
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1215
- Registration Number
- NCT00071279
- Locations
- 🇺🇸
Cardinal Bernardin Cancer Center, Maywood, Illinois, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation (AMADEUS)
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2003-10-09
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 4673
- Registration Number
- NCT00070655
- Locations
- 🇨🇦
Saskatoon Medical Specialists, Saskatoon, Saskatchewan, Canada
🇨🇦Health Care Corporation of St. John's Health Sciences Centre, St. John's, Newfoundland and Labrador, Canada
🇨🇦Yorkton Regional Health Centre, Yorkton, Saskatchewan, Canada
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: insulin glargine (HOE901)Drug: placeboDevice: reusable pen device for insulin injection
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 12537
- Registration Number
- NCT00069784
- Locations
- 🇻🇪
Makati City, Caracas, Venezuela
🇬🇧Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
🇷🇺Sanofi-Aventis Aministrative Office, Moscow, Russian Federation
A Phase II Trial of Adjuvant Docetaxel in Patients At High Risk of Relapse Following Prostatectomy
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 83
- Registration Number
- NCT00069888
- Locations
- 🇺🇸
Sanofi-Aventis US, Bridgewater, New Jersey, United States
Safety and Efficacy Trial Evaluating the Use of SR34006 in the Treatment of Deep Vein Thrombosis (DVT)
- Conditions
- Deep Vein Thrombosis
- First Posted Date
- 2003-08-13
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1452
- Registration Number
- NCT00067093
- Locations
- 🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸MIMA Century Research Associates, Melbourne, Florida, United States
🇺🇸Jackson Cardio-Vascular Clinic, Jacksonville, Florida, United States
SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
- Conditions
- Pulmonary Embolism
- First Posted Date
- 2003-06-17
- Last Posted Date
- 2009-04-29
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00062803
- Locations
- 🇺🇸
Loyola University Medical Center and Outpatient Clinic, Maywood, Illinois, United States
🇺🇸Akron General Medical Center, Akron, Ohio, United States
🇺🇸Mary Black Memorial Hospital, Spartanburg, South Carolina, United States
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-11-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3222
- Registration Number
- NCT00021255
- Locations
- 🇻🇪
Sanofi-Aventis Administrative Office, Caracas, Venezuela
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00012389
- Locations
- 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
🇺🇸Hematology Oncology Consultants Inc, Columbus, Ohio, United States
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
- Conditions
- Arteriosclerosis
- First Posted Date
- 2002-12-23
- Last Posted Date
- 2012-04-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15603
- Registration Number
- NCT00050817
- Locations
- 🇬🇧
Sanofi-aventis Administrative Office, Guildford Surrey, United Kingdom
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
- Conditions
- Diabetes Mellitus
- First Posted Date
- 2002-10-02
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 240
- Registration Number
- NCT00046462
- Locations
- 🇺🇸
Aventis, Bridgewater, New Jersey, United States